EA201391613A1 - КОМПОЗИЦИЯ АНТИ-α4β7 АНТИТЕЛА - Google Patents

КОМПОЗИЦИЯ АНТИ-α4β7 АНТИТЕЛА

Info

Publication number
EA201391613A1
EA201391613A1 EA201391613A EA201391613A EA201391613A1 EA 201391613 A1 EA201391613 A1 EA 201391613A1 EA 201391613 A EA201391613 A EA 201391613A EA 201391613 A EA201391613 A EA 201391613A EA 201391613 A1 EA201391613 A1 EA 201391613A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
compositions
antibodies
composition anti
provides
Prior art date
Application number
EA201391613A
Other languages
English (en)
Other versions
EA032625B1 (ru
EA201391613A8 (ru
Inventor
Уиллоу Дилузио
Пхоунг М. Нгуйен
Ксанад М. Варга
Ваитхианатхан Паланиаппан
Джейсон Браун
Ирвинг Х. Фокс
Кэтрин Сколз
Хелен Дженкинс
Мария Розарио
Original Assignee
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46147702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201391613(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Милленниум Фармасьютикалз, Инк. filed Critical Милленниум Фармасьютикалз, Инк.
Publication of EA201391613A1 publication Critical patent/EA201391613A1/ru
Publication of EA201391613A8 publication Critical patent/EA201391613A8/ru
Publication of EA032625B1 publication Critical patent/EA032625B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)

Abstract

Описаны композиции антител, включающие смесь анти-α4β7 антитела, антиоксиданта или хелатирующего агента и по меньшей мере одной свободной аминокислоты. Раскрытые композиции могут обладать улучшенной стабильностью, пониженным образованием агрегатов или обеими этими характеристиками. Настоящее изобретение дополнительно предусматривает безопасный режим дозирования таких композиций антител, который может легко соблюдаться и который обеспечивает терапевтически эффективное количество анти-α4β7 антитела in vivo.
EA201391613A 2011-05-02 2012-05-02 КОМПОЗИЦИЯ АНТИ-α4β7 АНТИТЕЛА EA032625B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161481522P 2011-05-02 2011-05-02
US201161544054P 2011-10-06 2011-10-06
PCT/US2012/036069 WO2012151247A2 (en) 2011-05-02 2012-05-02 FORMULATION FOR ANTI-α4β7 ANTIBODY

Publications (3)

Publication Number Publication Date
EA201391613A1 true EA201391613A1 (ru) 2014-07-30
EA201391613A8 EA201391613A8 (ru) 2016-05-31
EA032625B1 EA032625B1 (ru) 2019-06-28

Family

ID=46147702

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391613A EA032625B1 (ru) 2011-05-02 2012-05-02 КОМПОЗИЦИЯ АНТИ-α4β7 АНТИТЕЛА

Country Status (37)

Country Link
US (6) US10040855B2 (ru)
EP (3) EP4378959A2 (ru)
JP (5) JP6190359B2 (ru)
KR (7) KR20230021758A (ru)
CN (4) CN107998388B (ru)
AR (1) AR086238A1 (ru)
AU (5) AU2012250872B2 (ru)
CA (2) CA2834900C (ru)
CL (3) CL2013003145A1 (ru)
CO (1) CO6801648A2 (ru)
CR (1) CR20130556A (ru)
CY (1) CY1119436T1 (ru)
DK (1) DK2704742T3 (ru)
DO (1) DOP2013000252A (ru)
EA (1) EA032625B1 (ru)
EC (1) ECSP22046340A (ru)
ES (1) ES2646717T3 (ru)
GE (1) GEP20186866B (ru)
HK (1) HK1253911A1 (ru)
HR (1) HRP20171457T1 (ru)
HU (1) HUE036664T2 (ru)
IL (6) IL305583A (ru)
LT (1) LT2704742T (ru)
ME (1) ME02858B (ru)
MX (4) MX354101B (ru)
MY (1) MY188820A (ru)
PE (1) PE20141672A1 (ru)
PH (2) PH12018502221A1 (ru)
PL (1) PL2704742T3 (ru)
PT (1) PT2704742T (ru)
RS (1) RS56429B1 (ru)
SG (1) SG194730A1 (ru)
SI (1) SI2704742T1 (ru)
TW (5) TWI698254B (ru)
UY (1) UY34054A (ru)
WO (1) WO2012151247A2 (ru)
ZA (2) ZA201308168B (ru)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3459564T (pt) 2010-01-06 2022-01-31 Takeda Pharmaceuticals Co Proteínas de ligação à calicreína plasmática
SG189220A1 (en) * 2010-10-06 2013-05-31 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
KR102107695B1 (ko) 2011-01-06 2020-05-07 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
CN107998388B (zh) 2011-05-02 2023-07-14 千禧制药公司 抗α4β7抗体的制剂
SG10201605516YA (en) 2011-07-06 2016-08-30 Nestec Sa Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9764093B2 (en) * 2012-11-30 2017-09-19 Sio2 Medical Products, Inc. Controlling the uniformity of PECVD deposition
WO2014152232A2 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies
KR20220129671A (ko) * 2013-07-05 2022-09-23 인테그라 메디컬 인코포레이티드 구강 조성물
BR112016011224A2 (pt) * 2013-11-29 2017-09-19 Ares Trading Sa Formulação líquida de uma proteína de fusão que compreende tnfr e região de fc
KR20240033093A (ko) 2014-10-06 2024-03-12 케모센트릭스, 인크. C-c 케모카인 수용체 타입 9 (ccr9)의 억제제 및 항-알파4베타7 인테그린 차단 항체의 조합 요법
US20170327584A1 (en) 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease
US20180264111A1 (en) * 2014-12-03 2018-09-20 Csl Behring Gmbh Ag Pharmaceutical product with increased stability comprising immunoglobulins
SG11201704200SA (en) 2014-12-05 2017-06-29 Nestec Sa Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
JP6904905B2 (ja) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
EP3286226A4 (en) * 2015-03-30 2018-12-05 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN115400220A (zh) * 2015-12-30 2022-11-29 豪夫迈·罗氏有限公司 减少聚山梨酯降解的制剂
USD866757S1 (en) 2016-03-11 2019-11-12 Millennium Pharmaceuticals, Inc. Autoinjector
KR102667332B1 (ko) 2016-03-14 2024-05-20 밀레니엄 파머슈티컬스 인코퍼레이티드 이식편대숙주 질환을 치료하거나 예방하는 방법
MA44408A (fr) * 2016-03-14 2019-01-23 Millennium Pharm Inc Méthode de traitement de la réaction du greffon contre l'hôte (gvd)
EP3433275A1 (en) 2016-03-24 2019-01-30 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
MA44864A (fr) 2016-05-04 2019-03-13 Icahn School Med Mount Sinai Trithérapie pour le traitement d'une maladie intestinale inflammatoire
CN109414502A (zh) * 2016-06-12 2019-03-01 千禧制药公司 治疗炎症性肠病的方法
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
PE20191436A1 (es) * 2016-12-23 2019-10-14 Serum Institute Of India Pvt Ltd Metodos mejorados para estimular la productividad de anticuerpos en el cultivo de celulas de mamiferos y reducir la agregacion durante los procesos de formulacion post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
CN108686204A (zh) * 2017-04-07 2018-10-23 浙江海正药业股份有限公司 包含组氨酸缓冲体系的英夫利西单抗组合物
JP2020517671A (ja) 2017-04-28 2020-06-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小児の障害を処置する方法
RU2020111574A (ru) * 2017-08-25 2021-09-27 Омерос Корпорейшн Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом
BR112020020707A2 (pt) * 2018-04-10 2021-01-12 Dr. Reddy's Laboratories Limited Formulação farmacêutica estável de um anticorpo alfa4beta7
SG11202009876TA (en) * 2018-04-10 2020-11-27 Dr Reddy’s Laboratories Ltd Stable formulations of therapeutic antibody
SG11202009872YA (en) * 2018-04-10 2020-11-27 Dr Reddys Laboratories Ltd Stable antibody formulation
EP3843783A1 (en) * 2018-08-29 2021-07-07 GlaxoSmithKline Intellectual Property Development Limited Methods of preparing stable liquid therapeutic protein compositions
US20220142977A1 (en) * 2019-01-08 2022-05-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
WO2020252072A1 (en) * 2019-06-10 2020-12-17 Millennium Pharmaceuticals, Inc. Antibody purification methods and compositions thereof
WO2021070203A1 (en) * 2019-10-11 2021-04-15 Dr. Reddy's Laboratories Limited Stable formulation of integrin antibody
KR20230041071A (ko) * 2020-07-31 2023-03-23 제넨테크, 인크. 항-인테그린 베타7 항체 제제 및 장치
US20240101679A1 (en) * 2020-12-09 2024-03-28 Dr. Reddy’S Laboratories Limited Stable aqueous buffer free formulation of an integrin antibody
WO2022253994A1 (en) * 2021-06-04 2022-12-08 Polpharma Biologics S.A. Vedolizumab formulation
CN113813377A (zh) * 2021-09-07 2021-12-21 杭州远大生物制药有限公司 抗α4β7抗体制剂及其应用
WO2023126411A1 (en) 2021-12-27 2023-07-06 Polpharma Biologics S.A. Vedolizumab formulation
WO2023230620A1 (en) * 2022-05-27 2023-11-30 Sonnet BioTherapeutics, Inc. Il-12-albumin-binding domain fusion protein formulations and methods of use thereof

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
DE3852236T2 (de) 1987-08-11 1995-04-06 Univ Leland Stanford Junior Verfahren zur Kontrolle der Leukozyten-Extravasation.
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223392A (en) 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
EP0462111A4 (en) 1988-12-23 1992-07-08 The Board Of Trustees Of The Leland Stanford Junior University Homing sequences and their uses
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
IL113261A (en) 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Repression by peptides of lymphocyte binding to vascular endothelium by interaction of extracellular uterine capacitor with connective tissue, and pharmaceutical preparations containing
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
SK281142B6 (sk) 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Humanizovaná monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
US5665595A (en) 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
ATE151642T1 (de) 1992-02-12 1997-05-15 Biogen Inc Behandlung für entzündungserkrankung des darmes
AU4390893A (en) 1992-05-21 1993-12-13 Center For Blood Research, Inc., The A novel receptor for alpha4 integrins and methods based thereon
WO1994012214A1 (en) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
AU5675794A (en) 1992-12-15 1994-07-04 Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
DK0682529T4 (da) 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
US6017695A (en) 1993-03-26 2000-01-25 Becton Dickinson And Company Nucleic acids encoding human cell adhesion molecule
JPH06303990A (ja) 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
ES2424292T3 (es) 1994-01-25 2013-09-30 Biogen Idec Ma Inc. Anticuerpos humanizados contra la molécula de adhesión leucocitaria VLA-4
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5594120A (en) 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5624321A (en) 1994-12-23 1997-04-29 Snyder; Stephen D. Spring-actuated swing device
EP0808367B1 (en) 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
CA2385745C (en) * 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
RU2359697C2 (ru) 2002-02-25 2009-06-27 Элан Фармасьютикалз, Инк. Введение средств для лечения воспаления
WO2003099773A1 (en) 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
KR100866456B1 (ko) 2002-11-18 2008-10-31 케모센트릭스 아릴 술폰아마이드
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
EP1598074B1 (en) 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
ZA200507757B (en) * 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
HUE039591T2 (hu) 2004-09-03 2019-01-28 Genentech Inc Humanizált anti-béta7 antagonisták és alkalmazásaik
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
SI1865986T1 (sl) * 2005-03-08 2016-05-31 Pfizer Products Inc. Sestavki protitelesa proti CTLA-4
WO2007007159A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat uterine disorders
WO2007061679A1 (en) 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
CA2649907A1 (en) 2006-04-21 2007-11-01 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
US20110070225A1 (en) * 2006-11-12 2011-03-24 Pierre Goldbach Beta antibody parenteral formulation
EP2109480B1 (en) 2006-12-07 2017-06-28 The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin
WO2009009497A1 (en) 2007-07-06 2009-01-15 Stereotaxis, Inc. Management of live remote medical display
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP2220115A2 (en) * 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
WO2010107752A2 (en) * 2009-03-20 2010-09-23 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
CN101533504A (zh) * 2009-04-27 2009-09-16 刘文祥 电子医务系统及其装置
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN107998388B (zh) * 2011-05-02 2023-07-14 千禧制药公司 抗α4β7抗体的制剂

Also Published As

Publication number Publication date
ZA201707310B (en) 2022-04-28
MX354101B (es) 2018-02-13
KR102136208B1 (ko) 2020-07-21
KR20230021758A (ko) 2023-02-14
IL274846A (en) 2020-07-30
CN108969761A (zh) 2018-12-11
HK1253911A1 (zh) 2019-07-05
SI2704742T1 (sl) 2017-12-29
UY34054A (es) 2012-11-30
TW202317193A (zh) 2023-05-01
US20200377601A1 (en) 2020-12-03
TW201940195A (zh) 2019-10-16
GEP20186866B (en) 2018-06-25
HRP20171457T1 (hr) 2017-11-03
ES2646717T3 (es) 2017-12-15
CA3051418A1 (en) 2012-11-08
RS56429B1 (sr) 2018-01-31
CL2020001579A1 (es) 2020-11-06
AU2017204192A1 (en) 2017-07-13
CN103533959B (zh) 2018-06-05
NZ617340A (en) 2015-12-24
CA2834900A1 (en) 2012-11-08
AU2012250872A1 (en) 2013-11-21
KR102493433B1 (ko) 2023-01-27
CO6801648A2 (es) 2013-11-29
IL290848A (en) 2022-04-01
AU2021225160A1 (en) 2021-09-30
AU2012250872B2 (en) 2017-07-13
LT2704742T (lt) 2017-10-25
KR20210120144A (ko) 2021-10-06
CN107998388A (zh) 2018-05-08
TWI723339B (zh) 2021-04-01
TWI832619B (zh) 2024-02-11
CY1119436T1 (el) 2018-03-07
CA2834900C (en) 2021-03-02
EA032625B1 (ru) 2019-06-28
JP6190359B2 (ja) 2017-08-30
JP2017137353A (ja) 2017-08-10
JP6751450B2 (ja) 2020-09-02
PL2704742T3 (pl) 2018-01-31
CN107998388B (zh) 2023-07-14
PE20141672A1 (es) 2014-11-26
IL229169A0 (en) 2013-12-31
IL272237B (en) 2022-05-01
TW202133878A (zh) 2021-09-16
IL272237A (en) 2020-02-27
KR102014512B1 (ko) 2019-08-26
KR20140145952A (ko) 2014-12-24
BR112013028169A2 (pt) 2017-06-27
CN108969469A (zh) 2018-12-11
HUE036664T2 (hu) 2018-07-30
JP2014515763A (ja) 2014-07-03
PH12019501662A1 (en) 2021-03-15
IL290849A (en) 2022-04-01
KR102493433B9 (ko) 2023-09-01
CL2017000829A1 (es) 2017-12-29
TWI698254B (zh) 2020-07-11
WO2012151247A2 (en) 2012-11-08
SG194730A1 (en) 2013-12-30
MX2019009244A (es) 2019-09-13
EP4378959A2 (en) 2024-06-05
MX2021008112A (es) 2022-06-02
JP7107997B2 (ja) 2022-07-27
IL229169B (en) 2020-06-30
EP2704742B1 (en) 2017-07-12
MY188820A (en) 2022-01-05
PH12018502221A1 (en) 2019-10-28
JP2020180163A (ja) 2020-11-05
IL305583A (en) 2023-10-01
KR20180080354A (ko) 2018-07-11
AU2019216679B2 (en) 2021-09-23
US10040855B2 (en) 2018-08-07
KR20200088517A (ko) 2020-07-22
US20180327497A1 (en) 2018-11-15
AU2023274233A1 (en) 2023-12-21
ECSP22046340A (es) 2022-07-29
WO2012151247A3 (en) 2013-02-28
CN103533959A (zh) 2014-01-22
TW201300128A (zh) 2013-01-01
TWI799757B (zh) 2023-04-21
US20180346578A1 (en) 2018-12-06
TWI638661B (zh) 2018-10-21
KR101875155B1 (ko) 2018-07-09
CR20130556A (es) 2014-03-05
JP6467457B2 (ja) 2019-02-13
PT2704742T (pt) 2017-11-15
CA3051418C (en) 2021-05-18
AR086238A1 (es) 2013-11-27
EA201391613A8 (ru) 2016-05-31
KR101884406B1 (ko) 2018-08-02
EP3311834A1 (en) 2018-04-25
EP2704742A2 (en) 2014-03-12
AU2017204192B2 (en) 2019-09-12
TW201813665A (zh) 2018-04-16
JP2019052191A (ja) 2019-04-04
MX367097B (es) 2019-08-05
AU2019216679A1 (en) 2019-09-05
KR102308938B1 (ko) 2021-10-01
ME02858B (me) 2018-04-20
KR20170056713A (ko) 2017-05-23
DK2704742T3 (en) 2017-10-23
AU2021225160B2 (en) 2023-12-21
MX2013012725A (es) 2013-12-06
ZA201308168B (en) 2018-11-28
US20140341885A1 (en) 2014-11-20
US11560434B2 (en) 2023-01-24
JP2022132430A (ja) 2022-09-08
DOP2013000252A (es) 2013-12-31
US20230312727A1 (en) 2023-10-05
CL2013003145A1 (es) 2014-07-25
US20210340261A1 (en) 2021-11-04
KR20190100451A (ko) 2019-08-28

Similar Documents

Publication Publication Date Title
EA201391613A8 (ru) КОМПОЗИЦИЯ АНТИ-α4β7 АНТИТЕЛА
PH12020500336A1 (en) FORMULATION FOR ANTI-a4á7 ANTIBODY
EA201491644A1 (ru) Фармацевтические композиции
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MX351414B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
EA201301240A1 (ru) Полиморфная форма бензоата линаглиптина
EA201590887A1 (ru) Композиция
EA201490395A1 (ru) Способ получения фармацевтических композиций, содержащих финголимод
EA201391643A1 (ru) Составы с замедленным высвобождением парацетамола
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
EA201990056A1 (ru) КОМПОЗИЦИЯ АНТИ-α4β7 АНТИТЕЛА
UA112984C2 (uk) КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EA201992881A3 (ru) Композиция анти-47 антитела

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM